OncoDiscovery Award - A New Short-Term Funding Opportunity for Early-Career Medical Oncologists Around the World
Myelo 2026: Virtual Global Congress on Multiple Myeloma
Alberto Costa on a 45-Year Journey and Future Direction - European School of Oncology
OncoDaily Grand Rounds at ASCO 2026: Sarcoma Edition
Bishal Gyawali: Essential Primer on Navigating Clinical Trial Reports
Grand Rounds by OncoDaily: AI in Oncology Edition
Runcie C.W. Chidebe on GLOBOCAN 2022: Cancer Incidence and Mortality in Africa
10 Must-Read Posts in Immuno-Oncology This Week
Enter RS and clinical context to view RS category and trial-aligned interpretation for early HR+/HER2- breast cancer.
This calculator is intended for ER/PR+ HER2- breast cancer only
TAILORx (Node-negative): Demonstrated that chemotherapy provides minimal to no benefit for most patients with RS 11-25. For patients ≤50 years, some benefit may be seen in RS 16-25.
RxPONDER (Node-positive, 1-3 nodes): Showed that postmenopausal patients with RS 0-25 did not benefit from chemotherapy. Premenopausal patients derived benefit regardless of RS.
RS Categories:
Low
0-10
Intermediate
11-25
High
26-100
